Data Supports Tesamorelin as Effective for HIV-Associated NASH
Arcaion / Pixabay

Data Supports Tesamorelin as Effective for HIV-Associated NASH

  Biopharmaceutical company Theratechnologies Inc. recently announced that its therapy candidate tesamorelin is effective in the treatment of HIV-associated nonalcoholic steatohepatitis (NASH). According to new data, published in JCI Insight, tesamorelin…

Continue Reading Data Supports Tesamorelin as Effective for HIV-Associated NASH
MRFF Funding Promotes Treatment Development for Patients with Rare Diseases
https://pixabay.com/en/money-piggy-bank-coins-finance-2180338/

MRFF Funding Promotes Treatment Development for Patients with Rare Diseases

  When it comes to researching and finding treatments for rare diseases, funding plays a crucial role. Recently, the Medical Research Future Fund (MRFF) Stem Cell Therapies Mission presented Monash…

Continue Reading MRFF Funding Promotes Treatment Development for Patients with Rare Diseases
NAFLD and NASH Predicted to Be a Growing Health Emergency
https://pixabay.com/en/doctor-hospital-bed-delivery-labor-840127/

NAFLD and NASH Predicted to Be a Growing Health Emergency

  In a Business Wire press release, the Canadian NASH Network (CanNASH) shared the results of a recent study predicting a severe increase in cases of nonalcoholic fatty liver disease…

Continue Reading NAFLD and NASH Predicted to Be a Growing Health Emergency
Podcast Series Released to Increase Awareness and Education for Nonalcoholic Steatohepatitis
source: pixabay.com

Podcast Series Released to Increase Awareness and Education for Nonalcoholic Steatohepatitis

International Nonalcoholic Steatohepatitis (NASH) Day takes place on June 12th every year. This year, a 4 part podcast series was released by NASHNET as part of the continued effort to spread…

Continue Reading Podcast Series Released to Increase Awareness and Education for Nonalcoholic Steatohepatitis
A New Phase 2 Trial Begins for Experimental Nonalcoholic Steatohepatitis Treatment
source: pixabay.com

A New Phase 2 Trial Begins for Experimental Nonalcoholic Steatohepatitis Treatment

According to a story from globenewswire.com, the biotechnology company CytoDyn Inc. has recently announced the initiation of a phase 2 clinical trial. This clinical trial will be testing the company's…

Continue Reading A New Phase 2 Trial Begins for Experimental Nonalcoholic Steatohepatitis Treatment
International Nonalcoholic Steatohepatitis (NASH) Day Sparks New Collaboration for Research
source: pixabay.com

International Nonalcoholic Steatohepatitis (NASH) Day Sparks New Collaboration for Research

International NASH Day, or IND, began in 2018 to raise awareness of nonalcoholic steatohepatitis (NASH). This is the most advanced form of fatty liver disease. It is a progressive condition…

Continue Reading International Nonalcoholic Steatohepatitis (NASH) Day Sparks New Collaboration for Research
Study: EDP-305 for the Treatment of Primary Biliary Cholangitis
source: pixabay.com

Study: EDP-305 for the Treatment of Primary Biliary Cholangitis

Enanta Pharmaceuticals has recently released the results from the second phase of its INTREPID trial, which studied EDP-305 as a treatment for primary biliary cholangitis (PBC). The results were positive,…

Continue Reading Study: EDP-305 for the Treatment of Primary Biliary Cholangitis
Join This Webcast to Hear the Latest Update for a Phase IIb Nonalcoholic Steatohepatitis Trial
source: pixabay.com

Join This Webcast to Hear the Latest Update for a Phase IIb Nonalcoholic Steatohepatitis Trial

According to a story from Biotech-365, the biopharmaceutical company Inventiva has been forced to change its plans to announce the latest updates for its phase IIb clinical trial. This clinical…

Continue Reading Join This Webcast to Hear the Latest Update for a Phase IIb Nonalcoholic Steatohepatitis Trial
Study: Viking Therapeutics Evaluates VK2809 for Treatment of Non-Alcoholic Steatohepatitis (NASH)
luvqs / Pixabay

Study: Viking Therapeutics Evaluates VK2809 for Treatment of Non-Alcoholic Steatohepatitis (NASH)

  The FDA has recently approved of Viking Therapeutics' Investigational New Drug (IND) application, which allows patients to enroll in their clinical trials. In order to qualify for these trials,…

Continue Reading Study: Viking Therapeutics Evaluates VK2809 for Treatment of Non-Alcoholic Steatohepatitis (NASH)
Potential Treatment for Nonalcoholic Steatohepatitis Earns Fast Track Designation
sms467 / Pixabay

Potential Treatment for Nonalcoholic Steatohepatitis Earns Fast Track Designation

According to a story from sectorpublishingintelligence.co.uk, the drug company INVENTIVA's lead product candidate, known as lanifibranor, has earned Fast Track Designation from the US Food and Drug Administration (FDA) as…

Continue Reading Potential Treatment for Nonalcoholic Steatohepatitis Earns Fast Track Designation
Positive Results in Mouse Model for Experimental Drug Treating Liver Scarring Associated With Nonalcoholic Steatohepatitis (NASH)
Alexas_Fotos / Pixabay

Positive Results in Mouse Model for Experimental Drug Treating Liver Scarring Associated With Nonalcoholic Steatohepatitis (NASH)

According to a story from globenewswire.com, the biopharmaceutical company ContraVir Pharmaceuticals, Inc. has recently announced that its experimental drug CRV431 was able to successfully decrease scarring of the liver in…

Continue Reading Positive Results in Mouse Model for Experimental Drug Treating Liver Scarring Associated With Nonalcoholic Steatohepatitis (NASH)

The FDA’s Director of the Center for Drug Evaluation Discusses Accelerated Approvals

  In the mid-1980s the FDA was criticized for being slow in approving new drugs. In fact, a commission was formed as a result of the mounting criticism. Janet Woodcock,…

Continue Reading The FDA’s Director of the Center for Drug Evaluation Discusses Accelerated Approvals

Drug Start Up Founder Says Drugs Will Work For You– But They Don’t Know Why

Although somewhat of an exaggeration, the title of this article falls in line with the thinking of Insitro’s founder, Daphne Koller. In a recent interview with Bloomberg, Koller said that…

Continue Reading Drug Start Up Founder Says Drugs Will Work For You– But They Don’t Know Why

New Potential Primary Biliary Cholangitis Treatment Granted Breakthrough Therapy Designation

Researchers at GENFIT are excited about promising results from studies investigating a new potential therapy for PBC and NASH, two rare liver diseases. Primary Biliary Cholangitis Primary biliary cholangitis (PBC)…

Continue Reading New Potential Primary Biliary Cholangitis Treatment Granted Breakthrough Therapy Designation
Phase 3 Study Data Shows Obeticholic Acid Could Treat NASH-Linked Fibrosis
Source: Pixabay.com

Phase 3 Study Data Shows Obeticholic Acid Could Treat NASH-Linked Fibrosis

According to a press release from American biotechnology company Intercept Pharmaceuticals, the company recently released additional data supporting its phase 3 clinical trial of obeticholic acid (OCA) in the treatment…

Continue Reading Phase 3 Study Data Shows Obeticholic Acid Could Treat NASH-Linked Fibrosis
Close Menu